# Donor Stem Cell Transplant After Busulfan, Fludarabine, and Antithymocyte Globulin in Treating Patients With Hematological Cancer

> **NCT00627666** · PHASE2 · COMPLETED · sponsor: **Asan Medical Center** · enrollment: 52 (estimated)

## Conditions studied

- Leukemia
- Myelodysplastic Syndromes
- Myelodysplastic/Myeloproliferative Neoplasms

## Interventions

- **BIOLOGICAL:** anti-thymocyte globulin
- **DRUG:** busulfan
- **DRUG:** fludarabine phosphate
- **DRUG:** leucovorin calcium
- **DRUG:** methotrexate
- **PROCEDURE:** allogeneic bone marrow transplantation
- **PROCEDURE:** allogeneic hematopoietic stem cell transplantation
- **PROCEDURE:** nonmyeloablative allogeneic hematopoietic stem cell transplantation

## Key facts

- **NCT ID:** NCT00627666
- **Lead sponsor:** Asan Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-01
- **Primary completion:** 2010-06
- **Final completion:** 2010-06
- **Target enrollment:** 52 (ESTIMATED)
- **Last updated:** 2013-03-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00627666

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00627666, "Donor Stem Cell Transplant After Busulfan, Fludarabine, and Antithymocyte Globulin in Treating Patients With Hematological Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00627666. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*